Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparative gene expression analysis of splenic T cells derived from rapamycin and PBS-treated mice

ABSTRACT: Comparative gene expression analysis of splenic T cells derived from rapamycin and PBS-treated mice

PROVIDER: PRJNA593393 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comparative gene expression analysis of splenic T cells derived from rapamycin and PBS-treated mice

Project description:The macrolide rapamycin is known for its immunosuppressive properties since it inhibits mTOR (mammalian target of rapamycin), which activity affects differentiation and functions of various innate and adaptive immune cells involved in graft-versus-host disease development. Since rapamycin procures immunosuppressive effects on the immune response, rapamycin is an attractive candidate for graft-versus-host disease prevention after allogeneic bone marrow transplantation We used an MHC class I and II mismatched parent into F1 bone marrow transplantation mouse model to elucidate the mechanisms of rapamycin on T cells in the context of graft-versus-host disease prevention. To define the impact of rapamycin therapy on T cells gene expression profile, we performed mircoarray analysis and compared gene expression profiles of sorted splenic T cells from rapamycin and PBS treated mice

2020-07-22 | GSE141415 | GEO

Comparative gene expression analysis of cells derived from rapamycin and PBS-treated mice

Project description:Comparative gene expression analysis of cells derived from rapamycin and PBS-treated mice

| PRJNA593388 | ENA

Comparative gene expression analysis of ex vivo isolated myeloid-derived suppressor cells (MDSCs) derived from rapamycin and PBS-treated mice

Project description:The macrolide rapamycin is known for its immunosuppressive properties since it inhibits mTOR (mammalian target of rapamycin), which activity affects differentiation and functions of various innate and adaptive immune cells involved in graft-versus-host disease development. Since rapamycin procures immunosuppressive effects on the immune response, rapamycin is an attractive candidate for graft-versus-host disease prevention after allogeneic bone marrow transplantation. Recently, an activating effect of rapamycin on the function of myeloid-derived suppressor cells (MDSCs), a subset of immune suppressive cells of myeloid origin was reported. However, the effect of rapamycin treatment on MDSCs induction and function in the management of graft-versus-host disease is largely unknown. We used an MHC class I and II mismatched parent into F1 bone marrow transplantation mouse model to elucidate the mechanisms of rapamycin on MDSCs in the context of graft-versus-host disease prevention. To define the impact of rapamycin therapy on MDSCs gene expression profile, we performed mircoarray analysis and compared gene expression profiles of ex vivo isolated MDSCs from rapamycin and PBS treated mice

2020-07-21 | GSE141414 | GEO

Comparative gene expression analysis of ex vivo isolated myeloid-derived suppressor cells (MDSCs) derived from rapamycin and PBS-treated mice

Project description:Comparative gene expression analysis of ex vivo isolated myeloid-derived suppressor cells (MDSCs) derived from rapamycin and PBS-treated mice

| PRJNA593394 | ENA

Comparative gene expression analysis of cells derived from rapamycin and PBS-treated mice

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-07-21 | GSE141416 | GEO

Expression data from Rapamycin treated Peripheral blood derived macrophages

Project description:Macrophages are at the front line of the innate immune system and differentiate from monocytes after infiltrating the infected tissue. Metabolic pathways are central to macrophage biology. We studied transcriptional differences between Rapamycin treated in vitro activated macrophages and untreated peripheral blood derived in vitro actiavted macrophages. We used microarrays to detail the global programme of gene expression in Rapamycin treated adult blood derived M(IL-10) and M(IFN-γ) macrophages and untreated adult blood derived M(IL-10) and M(IFN-γ)macropahges

2018-12-19 | GSE124020 | GEO

Single-cell RNA sequencing (scRNA-seq) on Treg cells from PBS and STAg treated mice

Project description:To identify cell composition and characterize transcriptional regulation in regulatory T (Treg) cells derived from mice subjected to soluble tachyzoite antigen (STAg) of Toxoplasma gondii treatment, we prepared splenic CD4+CD25+ Treg cells from PBS and STAg treated mice, and performed scRNA-seq using the 10× Genomics method.

2020-12-31 | GSE132803 | GEO

Expression data from Rapamycin treated Peripheral blood derived macrophages

Project description:Expression data from Rapamycin treated Peripheral blood derived macrophages

| PRJNA510583 | ENA

Rapamycin treated CEM-C1 cells 3 hours

Project description:Drug resistance remains a major obstacle to successful cancer treatment. Here we use a novel approach to identify rapamycin as a glucocorticoid resistance reversal agent. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in Acute Lymphoblastic Leukemia (ALL) cells. The screen indicated the mTOR inhibitor rapamycin profile matched the signature of GC-sensitivity. We thus tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells, and found that it sensitized cells to glucocorticoid induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis, and that the combination of rapamycin and glucocorticoids has potential utility in ALL. Furthermore this approach represents a novel strategy for identification of promising combination therapies for cancer. Keywords: drug treatment

2006-09-14 | GSE5822 | GEO

Mouse thymic, splenic B cells and splenic DC immunopeptidome

Project description:C57BL/6 Mouse: I-Ab immunopeptidome presented by thymus, splenic B cells and splenic DCs. Human lymphoblastoid cells: HLA-DR immunopeptidome identified from different cell dilutions. Splenic B cells Files- B cells 1 (121616WTII), B cells 2 (072417MHCII-1), B cells 3(072417MHCII-2) Thymus Files-Thymus 1 (120116WTII), Thymus 2 (020617WT MHCII), Thymus 3 (061417MHCII WT-1), Thymus 4 (061417MHCII WT-2) Splenic DCs- DC1 (021517 Immature), DC2 (021517 Mature), DC3 (022018_BL6_Control), DC4 (022018_BL6_FLT3)

2021-03-10 | MSV000087031 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data